Day Trader's Alert: CHTP, ATHX, APP

Shares of Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) jumped more than 30% in pre-market trading Monday after the biotechnology company said that preliminary analyses of its Phase III NORTHERA Study 301 met its primary endpoint. Treatment with Northera provided clinically meaningful and statistically significant improvement in symptoms associated with neurogenic orthostatic hypotension, a chronic and often debilitating drop in blood pressure upon standing. Study results also showed that Northera was both safe and very well tolerated.

Athersys, Inc. (NASDAQ: ATHX) jumped more than 8% in pre-market trading after it announced the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University. This study demonstrates that intravenous injection of MultiStem(R), Athersys' multipotent adult progenitor stem cell therapy product, provides neurovascular protection after traumatic brain injury (TBI) in an established preclinical model of brain injury. The publication outlines how the administration of MultiStem enabled the preservation of the "blood brain barrier", and also reduced the effects and extent of the brain injury.

American Apparel, Inc. (AMEX: APP) late Friday announced that it received a letter from the NYSE Amex LLC (the "Exchange") that the Exchange accepted the company's updated plan of compliance and, pursuant to such plan, has granted the company an extension until November 15, 2010 to regain compliance with its continued listing standards.

Full Disclosure: None.